Praxis Precision Medicines, Inc.: two NDAs, relutrigine priority review, and DEE pipeline catalysts through 2027. Click for ...
BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines (PRAX), Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results